Cytology Assessment Can Predict Survival for Patients With Metastatic Pancreatic Neuroendocrine Neoplasms

被引:11
|
作者
Sigel, Carlie S. [1 ]
Guo, Huimin [1 ]
Sigel, Keith M. [2 ]
Zhang, Ming [1 ]
Rekhtman, Natasha [1 ]
Lin, Oscar [1 ]
Klimstra, David S. [1 ]
Jungbluth, Achim A. [1 ]
Tang, Laura K. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA
[2] Icahn Sch Med Mt Sinai, Div Gen Internal Med, New York, NY 10029 USA
基金
美国国家卫生研究院;
关键词
cytology; grade; differentiation; Ki-67; index; metastatic; neuroendocrine carcinoma; pancreas; pancreatic neuroendocrine tumor; HIGH-GRADE; LABELING INDEX; TUMORS; CARCINOMAS; DISTINCT; CELL;
D O I
10.1002/cncy.21817
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Histological features and Ki-67 index have known usefulness in predicting prognosis and guiding therapy among patients with metastatic pancreatic neuroendocrine neoplasms. Fine-needle aspiration may offer advantages for Ki-67 assessment because the technique obtains highly cellular, well-preserved specimens with the potential for broader tumor sampling. In the current study, the authors evaluated concordance for grade and differentiation between concurrent core needle biopsy and cytology preparations. Cytological features and grade then were correlated with survival. METHODS: Differentiation, grade by Ki-67 index, and correlation of these features with survival were compared between concurrent core needle biopsy and cytology specimens from 44 patients with metastatic pancreatic neuroendocrine neoplasms. RESULTS: Differentiation by cytology smear resulted in 38 cases of well (86%) and 6 cases of poor (14%) differentiation. Agreement for differentiation between smear and cell block, smear and core needle biopsy, and cell block and core needle biopsy was 88%, 94%, and 83%, respectively, and agreement for grade was 68%, 54%, and 22%, respectively. Cytology differentiation and cytology grade were found to be strong predictors of outcome with respective hazard ratios of 8.3 (95% confidence interval [95% CI], 3.1-22.1; P<.001) and 1.9 (95% CI, 1.2-2.9) for each ascending grade. The median disease-specific survival cytology projections were 121 months (95% CI, 57-185 months [estimated]) for grade 1, 45 months (95% CI, 29-87 months) for grade 2, and 19 months (95% CI, 1-44 months) for grade 3, with median survivals of 45 months and 3 months, respectively, for patients with well-differentiated and poorly differentiated neuroendocrine tumors (P<. 001). CONCLUSIONS: Grading of pancreatic neuroendocrine neoplasms on cytology may not correlate exactly with concurrent core needle biopsy, but cytology differentiation and grade are predictive of survival based on stage-adjusted analysis. (C) 2017 American Cancer Society.
引用
收藏
页码:188 / 196
页数:9
相关论文
共 50 条
  • [1] Dedifferentiation of Metastatic Pancreatic Neuroendocrine Neoplasms
    Alexandraki, K.
    Boutzios, G.
    Kaltsatou, M.
    Nikolopoulos, G.
    Moschouris, P.
    Chrysochoou, M.
    Kaltsas, G.
    NEUROENDOCRINOLOGY, 2017, 105 : 63 - 63
  • [2] Nomograms to predict the prognosis of pancreatic neuroendocrine neoplasms
    Bao, J.
    Bai, J. A.
    Hu, P.
    Tian, Y.
    Tang, Q.
    JOURNAL OF NEUROENDOCRINOLOGY, 2023, 35 : 60 - 60
  • [3] Can MDCT or EUS features predict the histopathological grading scheme of pancreatic neuroendocrine neoplasms?
    Zhu, Hui
    Ying, Lang
    Tang, Wei
    Yang, Xiujiang
    Sun, Bo
    RADIOLOGIA MEDICA, 2017, 122 (05): : 319 - 326
  • [4] Can MDCT or EUS features predict the histopathological grading scheme of pancreatic neuroendocrine neoplasms?
    Hui Zhu
    Lang Ying
    Wei Tang
    Xiujiang Yang
    Bo Sun
    La radiologia medica, 2017, 122 : 319 - 326
  • [5] Prognostic value of CT findings to predict survival outcomes in patients with pancreatic neuroendocrine neoplasms: a single institutional study of 161 patients
    Kim, Dong Wook
    Kim, Hyoung Jung
    Kim, Kyung Won
    Byun, Jae Ho
    Kim, So Yeon
    Song, Ki Byung
    Ramaiya, Nikhil H.
    Tirumani, Sree Harsha
    Hong, Seung-Mo
    EUROPEAN RADIOLOGY, 2016, 26 (05) : 1320 - 1329
  • [6] Importance of surgery in distant metastatic pancreatic neuroendocrine neoplasms
    Billmann, F.
    Niessen, A.
    Hackert, T.
    CHIRURGIE, 2022, 93 (08): : 758 - 764
  • [7] Prognostic value of CT findings to predict survival outcomes in patients with pancreatic neuroendocrine neoplasms: a single institutional study of 161 patients
    Dong Wook Kim
    Hyoung Jung Kim
    Kyung Won Kim
    Jae Ho Byun
    So Yeon Kim
    Ki Byung Song
    Nikhil H. Ramaiya
    Sree Harsha Tirumani
    Seung-Mo Hong
    European Radiology, 2016, 26 : 1320 - 1329
  • [8] Diabetes in Patients With Pancreatic Neuroendocrine Neoplasms
    Zhuge, Xiaoling
    Wang, Yajie
    Chen, Xiao
    Guo, Chuangen
    FRONTIERS IN ENDOCRINOLOGY, 2020, 11
  • [9] Prediction of survival and tumor recurrence in patients undergoing surgery for pancreatic neuroendocrine neoplasms
    Kaltenborn, Alexander
    Matzke, Svenja
    Kleine, Moritz
    Krech, Till
    Ramackers, Wolf
    Vondran, Florian W. R.
    Klempnauer, Juergen
    Bektas, Hueseyin
    Schrem, Harald
    JOURNAL OF SURGICAL ONCOLOGY, 2016, 113 (02) : 194 - 202
  • [10] Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer
    Deng, G. C.
    Lv, Y.
    Yan, H.
    Sun, D. C.
    Qu, T. T.
    Pan, Y. T.
    Han, Q. L.
    Dai, G. H.
    BMC CANCER, 2021, 21 (01)